1Richardson PD, Davies MJ, Born GV (1989) Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2:941-944.

2van der Wal AC, Becker AE, van der Loos CM, Das PK (1994) Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:36-44.

3Rajagopalan S, Meng XP, Ramasamy S, Harrison DG,Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98:2572-2579.

4Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, et al. (2002) Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels16:111-117.

5Bruemmer D, Collins AR, Noh G, Wang W, Territo M, et al. (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318-1331.

6Pedersen TX, Madsen M, Junker N, Christoffersen C, Vikesa J, et al. (2013) Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. Cardiovasc Res 98:352-359.

7Kurata M, Okura T, Watanabe S, Fukuoka T,Higaki J (2006) Osteopontin and carotid atherosclerosis in patients with essential hypertension. ClinSci (Lond) 111:319-324.

8Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, et al. (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 7:487-498.

9O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, et al. (1994) Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 145:883-894.

10Flores ME, Norgard M, Heinegard D, Reinholt FP, Andersson G (1992) RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp Cell Res 201:526-530.

11Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, et al. (1996) Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J BiolChem 271:28485-28491.

12Ito K, Kon S, Nakayama Y, Kurotaki D, Saito Y, et al. (2009)The differential amino acid requirement within osteopontin in alpha4 and alpha9 integrin-mediated cell binding and migration. Matrix Biol 28:11-19.

13Uchinaka A, Hamada Y, Mori S, Miyagawa S, Saito A, et al. (2015) SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis. Mol Cell Biochem 408:191-203.

14Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, et al. (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149:293-305.

15Wolak T, Sion-Vardi N, Novack V, Greenberg G, Szendro G, et al. (2013) N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am J Hypertens 26:326-333.

16Kurata M, Okura T, Kumon Y, Tagawa M, Watanabe H, et al. (2012) Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients. Hypertens Res 35:207-212.

17Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Shibata T, et al. (2006) A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26:1304-1309.

18Aono J, Suzuki J, Iwai M, Horiuchi M, Nagai T,et al. (2012) Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 32:1453-1459.

19Pei Z, Okura T, Nagao T, Enomoto D, Kukida M, et al. (2016) Osteopontin deficiency reduces kidney damage from hypercholesterolemia in Apolipoprotein E-deficient mice. Sci Rep 6:28882.

20Zheng W, Li R, Pan H, He D, Xu R, et al. (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappa B and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60:1957-1965.

21Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, et al. (1995) The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713-724.

22Nishimichi N, Higashikawa F, Kinoh HH, Tateishi Y, Matsuda H, et al. (2009) Polymeric osteopontin employs integrin alpha9 beta1 as a receptor and attracts neutrophils by presenting a de novo binding site. J BiolChem 284:14769-14776.

23Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, et al. (2013) Osteopontin mediates macrophage chemotaxis via alpha4 and alpha9 integrins and survival via the alpha4 integrin. J Cell Biochem114:1194-1202.

24Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, et al.(2014) Osteopontin signaling upregulates cyclooxygenase- 2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9 beta1 integrin. Oncogene 33:2295-2306.

25Krishnamurthy P, Peterson JT, Subramanian V, Singh M, Singh K (2009) Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol Cell Biochem322:53-62.

26Lai CF, Seshadri V, Huang K, Shao JS, Cai J,et al. (2006) An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98:1479-1489.

27Chen PY, Qin L, Baeyens N, Li G, Afolabi T, et al. (2015) Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest 125:4514-4528.

28Manka DR, Wiegman P, Din S, Sanders JM, Green SA, et al. (1999) Arterial injury increases expression of inflammatory adhesion molecules in the carotid arteries of apolipoprotein- E-deficient mice. J Vasc Res 36:372-378.

29Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, et al. (2014) Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci10:154-160.

30Kadoglou NP, Moustardas P, Katsimpoulas M, Kapelouzou A, Kostomitsopoulos N, et al. (2012) The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther 26:367-374.